In recent years, ICIs have been approved for the treatment of multiple cancer types by disrupting checkpoint proteins, including cytotoxic lymphocyte antigen 4 (CTLA-4), PD-1 and PD-L1 (ref. 7). The gene discussed is PDCD1; the disease is cancer.